Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

30.13USD
26 May 2017
Change (% chg)

$-0.23 (-0.76%)
Prev Close
$30.36
Open
$30.29
Day's High
$30.34
Day's Low
$30.00
Volume
44,054
Avg. Vol
74,768
52-wk High
$37.24
52-wk Low
$20.92

ENTA.OQ

Chart for ENTA.OQ

About

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets:... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $574.99
Shares Outstanding(Mil.): 19.08
Dividend: --
Yield (%): --

Financials

  ENTA.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.70 -- --
ROI: -4.91 -8.48 -5.42
ROE: -4.98 -11.31 -4.68

BRIEF-Enanta Pharmaceuticals reports Q2 loss per share $0.28

* Enanta Pharmaceuticals reports financial results for its fiscal second quarter ended March 31, 2017

May 08 2017

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

Apr 21 2017

BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B

* Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

Feb 27 2017

BRIEF-Enanta Pharmaceuticals Q1 loss per share $0.26

* Enanta Pharmaceuticals reports financial results for its fiscal first quarter ended december 31, 2016

Feb 08 2017

BRIEF-Enanta pharmaceuticals says EMA grants accelerated assessment for Abbvie's investigational HCV regimen of Glecaprevir/Pibrentasvir

* Says EMA grants accelerated assessment for Abbvie's investigational HCV Regimen Of Glecaprevir/Pibrentasvir

Jan 24 2017

BRIEF-Enanta reports high SVR12 rates achieved in Genotype 1 chronic HCV infected Japanese patients

* Enanta - in certain-1 study, 99 percent genotype 1 chronic hepatitis-C infected Japanese patients without cirrhosis got svr 12 with 8 weeks of G/P treatment

Jan 09 2017

More From Around the Web

Earnings vs. Estimates